APRE vs. BRNS, MRSN, ARTV, ELYM, XLO, ATHE, LVTX, LTRN, CLNN, and RNTX
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Barinthus Biotherapeutics (BRNS), Mersana Therapeutics (MRSN), Artiva Biotherapeutics (ARTV), Eliem Therapeutics (ELYM), Xilio Therapeutics (XLO), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Clene (CLNN), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.
Aprea Therapeutics vs. Its Competitors
Aprea Therapeutics (NASDAQ:APRE) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.
In the previous week, Barinthus Biotherapeutics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.
Aprea Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.8, suggesting that its stock price is 180% less volatile than the S&P 500.
Aprea Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 761.11%. Barinthus Biotherapeutics has a consensus price target of $6.25, indicating a potential upside of 534.52%. Given Aprea Therapeutics' higher possible upside, equities research analysts plainly believe Aprea Therapeutics is more favorable than Barinthus Biotherapeutics.
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Aprea Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Barinthus Biotherapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Barinthus Biotherapeutics' return on equity of -46.43% beat Aprea Therapeutics' return on equity.
Summary
Barinthus Biotherapeutics beats Aprea Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APRE) was last updated on 7/9/2025 by MarketBeat.com Staff
